Precision Oncology Trends
The latest news on precision oncology research trends.
Investigators reported that the classifier could correctly predict cancer type with over 94 percent accuracy and highlighted impacts in a commercially tested cohort.
The research may inform the use of a liquid biopsy assay for tracking SMM progression that improves on bone marrow aspirate analysis and is easier for patients to access.
The TuPro study will evaluate whether a comprehensive suite of routine and emerging tests can add value to treatment decision making and improve outcomes.
Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.
The test will be used in the trial to improve understanding of molecular resistance mechanisms to Pfizer's Lorviqua and other ALK inhibitors.
The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.
The Sentinel trial will enroll up to 100,000 patients with early-stage tumors to evaluate Strata's investigational liquid biopsy assay.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.